U.S. health agencies announced their intention to develop a universal vaccine technology that targets multiple strains of various viruses, including influenza and coronaviruses.

This initiative, termed the “Generation Gold Standard,” is reportedly backed by a $500 million investment from the government, as reported by Reuters.

The project, led by the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH), signifies a strategic shift in funding from solely focusing on COVID-19 to a broader study of various viruses.

Trials for the universal flu vaccine are anticipated to commence in 2026, with an FDA decision expected by 2029, according to HHS.

A spokesperson emphasized that the project represents a “cost-effective, accountable alternative” to existing COVID-19 vaccines and therapeutics.

Although specific funding details were not disclosed, the investment is expected to be facilitated by the Biomedical Advanced Research and Development Authority (BARDA), an agency within HHS dedicated to securing public health against pandemic threats.